AstraZeneca (LON:AZN) Earns Outperform Rating from Royal Bank Of Canada

AstraZeneca (LON:AZN)‘s stock had its “outperform” rating restated by equities research analysts at Royal Bank Of Canada in a research note issued to investors on Tuesday, Digital Look reports. They presently have a £145 price objective on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price objective would indicate a potential upside of 22.59% from the company’s previous close.

AZN has been the subject of several other reports. Citigroup boosted their target price on shares of AstraZeneca from £175 to £178 and gave the company a “buy” rating in a research report on Tuesday, July 28th. Jefferies Financial Group reissued a “buy” rating and set a £175 price objective on shares of AstraZeneca in a research report on Wednesday. Deutsche Bank Aktiengesellschaft restated a “sell” rating and issued a £115 price objective on shares of AstraZeneca in a research note on Wednesday, September 2nd. Finally, Berenberg Bank reaffirmed a “buy” rating and issued a £160 target price on shares of AstraZeneca in a report on Thursday, September 3rd. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, AstraZeneca has an average rating of “Moderate Buy” and an average target price of £151.14.

AstraZeneca Price Performance

LON AZN opened at £118.28 on Tuesday. The company has a 50-day moving average price of £124.79 and a 200-day moving average price of £136.10. AstraZeneca has a 52 week low of £107.84 and a 52 week high of £157.32. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 64.10. The firm has a market capitalization of £183.44 billion, a P/E ratio of 17.71, a PEG ratio of 0.86 and a beta of 0.20.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.